Don't like Allergan's stock volatility? Blame hedge funds, analyst says

Large glass office building

On Monday, Allergan reported 9.3% organic growth, posted a 35% cash flow margin, pledged to stay away from large buyouts for now and reaffirmed its plans to return cash to investors. But its stock slipped by as much as 4% during the day.

Why? Bernstein’s Ronny Gal has a theory: hedge fund ownership.

As Gal pointed out in a note to clients this week, Big Pharma companies tend to have hedge fund ownership of 3% or lower. Allergan, on the other hand? An “overwhelming” 17.7%, he wrote. That’s up quite a bit since the pre-Actavis days, too; hedge fund ownership sat at 4.1% under former skipper David Pyott.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Unlike other investors, who may be taking more of a long-term view of a company’s prospects, hedge funds like near-term catalysts, Gal noted.  

“In short, we think the direct explanation for the volatility is that Allergan's investor base is heavily tilted toward ‘fast-money’, and those trade around near-term events,” he said. In other words, the 4% drop--and others like it--are "not indicative of a quarter being particularly bad.”

And he doesn’t expect that to change any time soon, as long as the composition of Allergan’s investor base resembles its current composition.

Allergan might want to do something to make sure it doesn’t, though. “It behooves Allergan to change the mix of its owners over time,” Gal wrote, and he thinks the company can do it. For one, it’s arguably as well positioned as it was during Pyott’s time, which means “the same mix can be achieved,” he figures. A dividend, which would make the stock more attractive to nonactive managers, might help, too.

One other suggestion? "Allergan should spend more time in Iowa," he wrote.

Related Articles:
Allergan CEO tamps down Biogen buyout rumors amid Q2 earnings slip
Is Biogen the latest big biotech M&A target? Allergan and Merck are circling, WSJ says
With Allergan deal sealed, Teva turns its attention to branded M&A
Allergan launches $10B buyback, focuses on tuck-in deals
Allergan's on the M&A hunt, but don't confuse it with Valeant: CEO


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.